Roger Tell
Chief Tech/Sci/R&D Officer at ISOFOL MEDICAL AB
Roger Tell active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ISOFOL MEDICAL AB | Chief Tech/Sci/R&D Officer | 31/01/2019 | - |
| Chief Executive Officer | 21/06/2023 | 08/01/2024 | |
| VIVESTO AB | Director/Board Member | 24/05/2022 | - |
Career history of Roger Tell
Former positions of Roger Tell
| Companies | Position | Start | End |
|---|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - | 31/01/2019 |
Training of Roger Tell
| Karolinska Institutet | Doctorate Degree |
Statistics
International
| Sweden | 5 |
Operational
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ISOFOL MEDICAL AB | Health Technology |
| VIVESTO AB | Health Technology |
| Private companies | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Roger Tell
- Experience
